 | • レポートコード：MRC2-11QY11373 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は慢性血栓塞栓性肺高血圧症（CTEPH）のグローバル市場について調査・分析したレポートです。種類別（経胸壁心エコー検査（TTE）、換気灌流（V/Q）スキャン、肺血管造影、心臓カテーテル検査、コンピューター断層撮影（CT）肺血管造影、その他）市場規模、用途別（病院、外来手術センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別慢性血栓塞栓性肺高血圧症（CTEPH）の競争状況、市場シェア ・世界の慢性血栓塞栓性肺高血圧症（CTEPH）市場：種類別市場規模 2015年-2020年（経胸壁心エコー検査（TTE）、換気灌流（V/Q）スキャン、肺血管造影、心臓カテーテル検査、コンピューター断層撮影（CT）肺血管造影、その他） ・世界の慢性血栓塞栓性肺高血圧症（CTEPH）市場：種類別市場規模予測 2021年-2026年（経胸壁心エコー検査（TTE）、換気灌流（V/Q）スキャン、肺血管造影、心臓カテーテル検査、コンピューター断層撮影（CT）肺血管造影、その他） ・世界の慢性血栓塞栓性肺高血圧症（CTEPH）市場：用途別市場規模 2015年-2020年（病院、外来手術センター、その他） ・世界の慢性血栓塞栓性肺高血圧症（CTEPH）市場：用途別市場規模予測 2021年-2026年（病院、外来手術センター、その他） ・北米の慢性血栓塞栓性肺高血圧症（CTEPH）市場分析：米国、カナダ ・ヨーロッパの慢性血栓塞栓性肺高血圧症（CTEPH）市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの慢性血栓塞栓性肺高血圧症（CTEPH）市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の慢性血栓塞栓性肺高血圧症（CTEPH）市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの慢性血栓塞栓性肺高血圧症（CTEPH）市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Bayer、Johnson & Johnson、Nippon Shinyaku、GlaxoSmithKline、Sun Pharmaceutical Industries、Scipharm SaRL、Promedica International、Medical Research Network、Gilead Sciences、Daiichi Sankyo ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Chronic thromboembolic pulmonary hypertension is observed to be one of the leading causes of severe pulmonary hypertension. It is a type of clinical condition in which pulmonary vascular resistance increases giving rise to pulmonary hypertension and progressive heart failure. According to World Health Organization (WHO), approximately 0.15% to 0.55% of the patients suffering with acute pulmonary embolism develop chronic thromboembolic pulmonary hypertension. Due to non-specific symptoms observed in chronic thromboembolic pulmonary hypertension its diagnosis is complex. However, some of the prominent symptoms of chronic thromboembolic pulmonary hypertension are chest discomfort, breathlessness and fatigue. Chronic thromboembolic pulmonary hypertension market can be segmented on the basis of types of diagnosis such as transthoracic echocardiogram (TTE), ventilation-perfusion (V/Q) scan, pulmonary angiography, heart catheterization, computed tomography (CT) pulmonary angiography and other pulmonary function tests.
According to market experts, the diagnosis cases of chronic thromboembolic pulmonary hypertension in regions such as Western Europe and North America was high due to presence of modern technology and rising public awareness about this disease. Regions with rare cases included Asia-Pacific and other geographic regions due to low public awareness and absence of modern diagnostic technologies. North America was observed to be the largest market due to increasing awareness related with chronic thromboembolic pulmonary hypertension and high R&D investments in novel disease diagnostic and treatment technologies.
Market Analysis and Insights: Global Chronic Thromboembolic Pulmonary Hypertension Market
The global Chronic Thromboembolic Pulmonary Hypertension market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Chronic Thromboembolic Pulmonary Hypertension Scope and Market Size
Chronic Thromboembolic Pulmonary Hypertension market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Chronic Thromboembolic Pulmonary Hypertension market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Bayer
Johnson & Johnson
Nippon Shinyaku
GlaxoSmithKline
Sun Pharmaceutical Industries
Scipharm SaRL
Promedica International
Medical Research Network
Gilead Sciences
Daiichi Sankyo
Market segment by Type, the product can be split into
Transthoracic Echocardiogram (TTE)
Ventilation-Perfusion (V/Q) Scan
Pulmonary Angiography
Heart Catheterization
Computed Tomography (CT) Pulmonary Angiography
Others
Market segment by Application, split into
Hospitals
Ambulatory Surgical Centers
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Chronic Thromboembolic Pulmonary Hypertension Revenue
1.4 Market by Type
1.4.1 Global Chronic Thromboembolic Pulmonary Hypertension Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Transthoracic Echocardiogram (TTE)
1.4.3 Ventilation-Perfusion (V/Q) Scan
1.4.4 Pulmonary Angiography
1.4.5 Heart Catheterization
1.4.6 Computed Tomography (CT) Pulmonary Angiography
1.4.7 Others
1.5 Market by Application
1.5.1 Global Chronic Thromboembolic Pulmonary Hypertension Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Ambulatory Surgical Centers
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Chronic Thromboembolic Pulmonary Hypertension Market Perspective (2015-2026)
2.2 Global Chronic Thromboembolic Pulmonary Hypertension Growth Trends by Regions
2.2.1 Chronic Thromboembolic Pulmonary Hypertension Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Chronic Thromboembolic Pulmonary Hypertension Historic Market Share by Regions (2015-2020)
2.2.3 Chronic Thromboembolic Pulmonary Hypertension Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Chronic Thromboembolic Pulmonary Hypertension Market Growth Strategy
2.3.6 Primary Interviews with Key Chronic Thromboembolic Pulmonary Hypertension Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Chronic Thromboembolic Pulmonary Hypertension Players by Market Size
3.1.1 Global Top Chronic Thromboembolic Pulmonary Hypertension Players by Revenue (2015-2020)
3.1.2 Global Chronic Thromboembolic Pulmonary Hypertension Revenue Market Share by Players (2015-2020)
3.1.3 Global Chronic Thromboembolic Pulmonary Hypertension Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Chronic Thromboembolic Pulmonary Hypertension Market Concentration Ratio
3.2.1 Global Chronic Thromboembolic Pulmonary Hypertension Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Chronic Thromboembolic Pulmonary Hypertension Revenue in 2019
3.3 Chronic Thromboembolic Pulmonary Hypertension Key Players Head office and Area Served
3.4 Key Players Chronic Thromboembolic Pulmonary Hypertension Product Solution and Service
3.5 Date of Enter into Chronic Thromboembolic Pulmonary Hypertension Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Chronic Thromboembolic Pulmonary Hypertension Historic Market Size by Type (2015-2020)
4.2 Global Chronic Thromboembolic Pulmonary Hypertension Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Chronic Thromboembolic Pulmonary Hypertension Market Size by Application (2015-2020)
5.2 Global Chronic Thromboembolic Pulmonary Hypertension Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Chronic Thromboembolic Pulmonary Hypertension Market Size (2015-2020)
6.2 Chronic Thromboembolic Pulmonary Hypertension Key Players in North America (2019-2020)
6.3 North America Chronic Thromboembolic Pulmonary Hypertension Market Size by Type (2015-2020)
6.4 North America Chronic Thromboembolic Pulmonary Hypertension Market Size by Application (2015-2020)
7 Europe
7.1 Europe Chronic Thromboembolic Pulmonary Hypertension Market Size (2015-2020)
7.2 Chronic Thromboembolic Pulmonary Hypertension Key Players in Europe (2019-2020)
7.3 Europe Chronic Thromboembolic Pulmonary Hypertension Market Size by Type (2015-2020)
7.4 Europe Chronic Thromboembolic Pulmonary Hypertension Market Size by Application (2015-2020)
8 China
8.1 China Chronic Thromboembolic Pulmonary Hypertension Market Size (2015-2020)
8.2 Chronic Thromboembolic Pulmonary Hypertension Key Players in China (2019-2020)
8.3 China Chronic Thromboembolic Pulmonary Hypertension Market Size by Type (2015-2020)
8.4 China Chronic Thromboembolic Pulmonary Hypertension Market Size by Application (2015-2020)
9 Japan
9.1 Japan Chronic Thromboembolic Pulmonary Hypertension Market Size (2015-2020)
9.2 Chronic Thromboembolic Pulmonary Hypertension Key Players in Japan (2019-2020)
9.3 Japan Chronic Thromboembolic Pulmonary Hypertension Market Size by Type (2015-2020)
9.4 Japan Chronic Thromboembolic Pulmonary Hypertension Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Chronic Thromboembolic Pulmonary Hypertension Market Size (2015-2020)
10.2 Chronic Thromboembolic Pulmonary Hypertension Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Chronic Thromboembolic Pulmonary Hypertension Market Size by Type (2015-2020)
10.4 Southeast Asia Chronic Thromboembolic Pulmonary Hypertension Market Size by Application (2015-2020)
11 India
11.1 India Chronic Thromboembolic Pulmonary Hypertension Market Size (2015-2020)
11.2 Chronic Thromboembolic Pulmonary Hypertension Key Players in India (2019-2020)
11.3 India Chronic Thromboembolic Pulmonary Hypertension Market Size by Type (2015-2020)
11.4 India Chronic Thromboembolic Pulmonary Hypertension Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Chronic Thromboembolic Pulmonary Hypertension Market Size (2015-2020)
12.2 Chronic Thromboembolic Pulmonary Hypertension Key Players in Central & South America (2019-2020)
12.3 Central & South America Chronic Thromboembolic Pulmonary Hypertension Market Size by Type (2015-2020)
12.4 Central & South America Chronic Thromboembolic Pulmonary Hypertension Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Bayer
13.1.1 Bayer Company Details
13.1.2 Bayer Business Overview
13.1.3 Bayer Chronic Thromboembolic Pulmonary Hypertension Introduction
13.1.4 Bayer Revenue in Chronic Thromboembolic Pulmonary Hypertension Business (2015-2020))
13.1.5 Bayer Recent Development
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Details
13.2.2 Johnson & Johnson Business Overview
13.2.3 Johnson & Johnson Chronic Thromboembolic Pulmonary Hypertension Introduction
13.2.4 Johnson & Johnson Revenue in Chronic Thromboembolic Pulmonary Hypertension Business (2015-2020)
13.2.5 Johnson & Johnson Recent Development
13.3 Nippon Shinyaku
13.3.1 Nippon Shinyaku Company Details
13.3.2 Nippon Shinyaku Business Overview
13.3.3 Nippon Shinyaku Chronic Thromboembolic Pulmonary Hypertension Introduction
13.3.4 Nippon Shinyaku Revenue in Chronic Thromboembolic Pulmonary Hypertension Business (2015-2020)
13.3.5 Nippon Shinyaku Recent Development
13.4 GlaxoSmithKline
13.4.1 GlaxoSmithKline Company Details
13.4.2 GlaxoSmithKline Business Overview
13.4.3 GlaxoSmithKline Chronic Thromboembolic Pulmonary Hypertension Introduction
13.4.4 GlaxoSmithKline Revenue in Chronic Thromboembolic Pulmonary Hypertension Business (2015-2020)
13.4.5 GlaxoSmithKline Recent Development
13.5 Sun Pharmaceutical Industries
13.5.1 Sun Pharmaceutical Industries Company Details
13.5.2 Sun Pharmaceutical Industries Business Overview
13.5.3 Sun Pharmaceutical Industries Chronic Thromboembolic Pulmonary Hypertension Introduction
13.5.4 Sun Pharmaceutical Industries Revenue in Chronic Thromboembolic Pulmonary Hypertension Business (2015-2020)
13.5.5 Sun Pharmaceutical Industries Recent Development
13.6 Scipharm SaRL
13.6.1 Scipharm SaRL Company Details
13.6.2 Scipharm SaRL Business Overview
13.6.3 Scipharm SaRL Chronic Thromboembolic Pulmonary Hypertension Introduction
13.6.4 Scipharm SaRL Revenue in Chronic Thromboembolic Pulmonary Hypertension Business (2015-2020)
13.6.5 Scipharm SaRL Recent Development
13.7 Promedica International
13.7.1 Promedica International Company Details
13.7.2 Promedica International Business Overview
13.7.3 Promedica International Chronic Thromboembolic Pulmonary Hypertension Introduction
13.7.4 Promedica International Revenue in Chronic Thromboembolic Pulmonary Hypertension Business (2015-2020)
13.7.5 Promedica International Recent Development
13.8 Medical Research Network
13.8.1 Medical Research Network Company Details
13.8.2 Medical Research Network Business Overview
13.8.3 Medical Research Network Chronic Thromboembolic Pulmonary Hypertension Introduction
13.8.4 Medical Research Network Revenue in Chronic Thromboembolic Pulmonary Hypertension Business (2015-2020)
13.8.5 Medical Research Network Recent Development
13.9 Gilead Sciences
13.9.1 Gilead Sciences Company Details
13.9.2 Gilead Sciences Business Overview
13.9.3 Gilead Sciences Chronic Thromboembolic Pulmonary Hypertension Introduction
13.9.4 Gilead Sciences Revenue in Chronic Thromboembolic Pulmonary Hypertension Business (2015-2020)
13.9.5 Gilead Sciences Recent Development
13.10 Daiichi Sankyo
13.10.1 Daiichi Sankyo Company Details
13.10.2 Daiichi Sankyo Business Overview
13.10.3 Daiichi Sankyo Chronic Thromboembolic Pulmonary Hypertension Introduction
13.10.4 Daiichi Sankyo Revenue in Chronic Thromboembolic Pulmonary Hypertension Business (2015-2020)
13.10.5 Daiichi Sankyo Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Chronic Thromboembolic Pulmonary Hypertension Key Market Segments
Table 2. Key Players Covered: Ranking by Chronic Thromboembolic Pulmonary Hypertension Revenue
Table 3. Ranking of Global Top Chronic Thromboembolic Pulmonary Hypertension Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Chronic Thromboembolic Pulmonary Hypertension Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Transthoracic Echocardiogram (TTE)
Table 6. Key Players of Ventilation-Perfusion (V/Q) Scan
Table 7. Key Players of Pulmonary Angiography
Table 8. Key Players of Heart Catheterization
Table 9. Key Players of Computed Tomography (CT) Pulmonary Angiography
Table 10. Key Players of Others
Table 11. Global Chronic Thromboembolic Pulmonary Hypertension Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 12. Global Chronic Thromboembolic Pulmonary Hypertension Market Size by Regions (US$ Million): 2020 VS 2026
Table 13. Global Chronic Thromboembolic Pulmonary Hypertension Market Size by Regions (2015-2020) (US$ Million)
Table 14. Global Chronic Thromboembolic Pulmonary Hypertension Market Share by Regions (2015-2020)
Table 15. Global Chronic Thromboembolic Pulmonary Hypertension Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 16. Global Chronic Thromboembolic Pulmonary Hypertension Market Share by Regions (2021-2026)
Table 17. Market Top Trends
Table 18. Key Drivers: Impact Analysis
Table 19. Key Challenges
Table 20. Chronic Thromboembolic Pulmonary Hypertension Market Growth Strategy
Table 21. Main Points Interviewed from Key Chronic Thromboembolic Pulmonary Hypertension Players
Table 22. Global Chronic Thromboembolic Pulmonary Hypertension Revenue by Players (2015-2020) (Million US$)
Table 23. Global Chronic Thromboembolic Pulmonary Hypertension Market Share by Players (2015-2020)
Table 24. Global Top Chronic Thromboembolic Pulmonary Hypertension Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Thromboembolic Pulmonary Hypertension as of 2019)
Table 25. Global Chronic Thromboembolic Pulmonary Hypertension by Players Market Concentration Ratio (CR5 and HHI)
Table 26. Key Players Headquarters and Area Served
Table 27. Key Players Chronic Thromboembolic Pulmonary Hypertension Product Solution and Service
Table 28. Date of Enter into Chronic Thromboembolic Pulmonary Hypertension Market
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Chronic Thromboembolic Pulmonary Hypertension Market Size by Type (2015-2020) (Million US$)
Table 31. Global Chronic Thromboembolic Pulmonary Hypertension Market Size Share by Type (2015-2020)
Table 32. Global Chronic Thromboembolic Pulmonary Hypertension Revenue Market Share by Type (2021-2026)
Table 33. Global Chronic Thromboembolic Pulmonary Hypertension Market Size Share by Application (2015-2020)
Table 34. Global Chronic Thromboembolic Pulmonary Hypertension Market Size by Application (2015-2020) (Million US$)
Table 35. Global Chronic Thromboembolic Pulmonary Hypertension Market Size Share by Application (2021-2026)
Table 36. North America Key Players Chronic Thromboembolic Pulmonary Hypertension Revenue (2019-2020) (Million US$)
Table 37. North America Key Players Chronic Thromboembolic Pulmonary Hypertension Market Share (2019-2020)
Table 38. North America Chronic Thromboembolic Pulmonary Hypertension Market Size by Type (2015-2020) (Million US$)
Table 39. North America Chronic Thromboembolic Pulmonary Hypertension Market Share by Type (2015-2020)
Table 40. North America Chronic Thromboembolic Pulmonary Hypertension Market Size by Application (2015-2020) (Million US$)
Table 41. North America Chronic Thromboembolic Pulmonary Hypertension Market Share by Application (2015-2020)
Table 42. Europe Key Players Chronic Thromboembolic Pulmonary Hypertension Revenue (2019-2020) (Million US$)
Table 43. Europe Key Players Chronic Thromboembolic Pulmonary Hypertension Market Share (2019-2020)
Table 44. Europe Chronic Thromboembolic Pulmonary Hypertension Market Size by Type (2015-2020) (Million US$)
Table 45. Europe Chronic Thromboembolic Pulmonary Hypertension Market Share by Type (2015-2020)
Table 46. Europe Chronic Thromboembolic Pulmonary Hypertension Market Size by Application (2015-2020) (Million US$)
Table 47. Europe Chronic Thromboembolic Pulmonary Hypertension Market Share by Application (2015-2020)
Table 48. China Key Players Chronic Thromboembolic Pulmonary Hypertension Revenue (2019-2020) (Million US$)
Table 49. China Key Players Chronic Thromboembolic Pulmonary Hypertension Market Share (2019-2020)
Table 50. China Chronic Thromboembolic Pulmonary Hypertension Market Size by Type (2015-2020) (Million US$)
Table 51. China Chronic Thromboembolic Pulmonary Hypertension Market Share by Type (2015-2020)
Table 52. China Chronic Thromboembolic Pulmonary Hypertension Market Size by Application (2015-2020) (Million US$)
Table 53. China Chronic Thromboembolic Pulmonary Hypertension Market Share by Application (2015-2020)
Table 54. Japan Key Players Chronic Thromboembolic Pulmonary Hypertension Revenue (2019-2020) (Million US$)
Table 55. Japan Key Players Chronic Thromboembolic Pulmonary Hypertension Market Share (2019-2020)
Table 56. Japan Chronic Thromboembolic Pulmonary Hypertension Market Size by Type (2015-2020) (Million US$)
Table 57. Japan Chronic Thromboembolic Pulmonary Hypertension Market Share by Type (2015-2020)
Table 58. Japan Chronic Thromboembolic Pulmonary Hypertension Market Size by Application (2015-2020) (Million US$)
Table 59. Japan Chronic Thromboembolic Pulmonary Hypertension Market Share by Application (2015-2020)
Table 60. Southeast Asia Key Players Chronic Thromboembolic Pulmonary Hypertension Revenue (2019-2020) (Million US$)
Table 61. Southeast Asia Key Players Chronic Thromboembolic Pulmonary Hypertension Market Share (2019-2020)
Table 62. Southeast Asia Chronic Thromboembolic Pulmonary Hypertension Market Size by Type (2015-2020) (Million US$)
Table 63. Southeast Asia Chronic Thromboembolic Pulmonary Hypertension Market Share by Type (2015-2020)
Table 64. Southeast Asia Chronic Thromboembolic Pulmonary Hypertension Market Size by Application (2015-2020) (Million US$)
Table 65. Southeast Asia Chronic Thromboembolic Pulmonary Hypertension Market Share by Application (2015-2020)
Table 66. India Key Players Chronic Thromboembolic Pulmonary Hypertension Revenue (2019-2020) (Million US$)
Table 67. India Key Players Chronic Thromboembolic Pulmonary Hypertension Market Share (2019-2020)
Table 68. India Chronic Thromboembolic Pulmonary Hypertension Market Size by Type (2015-2020) (Million US$)
Table 69. India Chronic Thromboembolic Pulmonary Hypertension Market Share by Type (2015-2020)
Table 70. India Chronic Thromboembolic Pulmonary Hypertension Market Size by Application (2015-2020) (Million US$)
Table 71. India Chronic Thromboembolic Pulmonary Hypertension Market Share by Application (2015-2020)
Table 72. Central & South America Key Players Chronic Thromboembolic Pulmonary Hypertension Revenue (2019-2020) (Million US$)
Table 73. Central & South America Key Players Chronic Thromboembolic Pulmonary Hypertension Market Share (2019-2020)
Table 74. Central & South America Chronic Thromboembolic Pulmonary Hypertension Market Size by Type (2015-2020) (Million US$)
Table 75. Central & South America Chronic Thromboembolic Pulmonary Hypertension Market Share by Type (2015-2020)
Table 76. Central & South America Chronic Thromboembolic Pulmonary Hypertension Market Size by Application (2015-2020) (Million US$)
Table 77. Central & South America Chronic Thromboembolic Pulmonary Hypertension Market Share by Application (2015-2020)
Table 78. Bayer Company Details
Table 79. Bayer Business Overview
Table 80. Bayer Product
Table 81. Bayer Revenue in Chronic Thromboembolic Pulmonary Hypertension Business (2015-2020) (Million US$)
Table 82. Bayer Recent Development
Table 83. Johnson & Johnson Company Details
Table 84. Johnson & Johnson Business Overview
Table 85. Johnson & Johnson Product
Table 86. Johnson & Johnson Revenue in Chronic Thromboembolic Pulmonary Hypertension Business (2015-2020) (Million US$)
Table 87. Johnson & Johnson Recent Development
Table 88. Nippon Shinyaku Company Details
Table 89. Nippon Shinyaku Business Overview
Table 90. Nippon Shinyaku Product
Table 91. Nippon Shinyaku Revenue in Chronic Thromboembolic Pulmonary Hypertension Business (2015-2020) (Million US$)
Table 92. Nippon Shinyaku Recent Development
Table 93. GlaxoSmithKline Company Details
Table 94. GlaxoSmithKline Business Overview
Table 95. GlaxoSmithKline Product
Table 96. GlaxoSmithKline Revenue in Chronic Thromboembolic Pulmonary Hypertension Business (2015-2020) (Million US$)
Table 97. GlaxoSmithKline Recent Development
Table 98. Sun Pharmaceutical Industries Company Details
Table 99. Sun Pharmaceutical Industries Business Overview
Table 100. Sun Pharmaceutical Industries Product
Table 101. Sun Pharmaceutical Industries Revenue in Chronic Thromboembolic Pulmonary Hypertension Business (2015-2020) (Million US$)
Table 102. Sun Pharmaceutical Industries Recent Development
Table 103. Scipharm SaRL Company Details
Table 104. Scipharm SaRL Business Overview
Table 105. Scipharm SaRL Product
Table 106. Scipharm SaRL Revenue in Chronic Thromboembolic Pulmonary Hypertension Business (2015-2020) (Million US$)
Table 107. Scipharm SaRL Recent Development
Table 108. Promedica International Company Details
Table 109. Promedica International Business Overview
Table 110. Promedica International Product
Table 111. Promedica International Revenue in Chronic Thromboembolic Pulmonary Hypertension Business (2015-2020) (Million US$)
Table 112. Promedica International Recent Development
Table 113. Medical Research Network Business Overview
Table 114. Medical Research Network Product
Table 115. Medical Research Network Company Details
Table 116. Medical Research Network Revenue in Chronic Thromboembolic Pulmonary Hypertension Business (2015-2020) (Million US$)
Table 117. Medical Research Network Recent Development
Table 118. Gilead Sciences Company Details
Table 119. Gilead Sciences Business Overview
Table 120. Gilead Sciences Product
Table 121. Gilead Sciences Revenue in Chronic Thromboembolic Pulmonary Hypertension Business (2015-2020) (Million US$)
Table 122. Gilead Sciences Recent Development
Table 123. Daiichi Sankyo Company Details
Table 124. Daiichi Sankyo Business Overview
Table 125. Daiichi Sankyo Product
Table 126. Daiichi Sankyo Revenue in Chronic Thromboembolic Pulmonary Hypertension Business (2015-2020) (Million US$)
Table 127. Daiichi Sankyo Recent Development
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chronic Thromboembolic Pulmonary Hypertension Market Share by Type: 2020 VS 2026
Figure 2. Transthoracic Echocardiogram (TTE) Features
Figure 3. Ventilation-Perfusion (V/Q) Scan Features
Figure 4. Pulmonary Angiography Features
Figure 5. Heart Catheterization Features
Figure 6. Computed Tomography (CT) Pulmonary Angiography Features
Figure 7. Others Features
Figure 8. Global Chronic Thromboembolic Pulmonary Hypertension Market Share by Application: 2020 VS 2026
Figure 9. Hospitals Case Studies
Figure 10. Ambulatory Surgical Centers Case Studies
Figure 11. Others Case Studies
Figure 12. Chronic Thromboembolic Pulmonary Hypertension Report Years Considered
Figure 13. Global Chronic Thromboembolic Pulmonary Hypertension Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global Chronic Thromboembolic Pulmonary Hypertension Market Share by Regions: 2020 VS 2026
Figure 15. Global Chronic Thromboembolic Pulmonary Hypertension Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global Chronic Thromboembolic Pulmonary Hypertension Market Share by Players in 2019
Figure 18. Global Top Chronic Thromboembolic Pulmonary Hypertension Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Thromboembolic Pulmonary Hypertension as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Chronic Thromboembolic Pulmonary Hypertension Revenue in 2019
Figure 20. North America Chronic Thromboembolic Pulmonary Hypertension Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe Chronic Thromboembolic Pulmonary Hypertension Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China Chronic Thromboembolic Pulmonary Hypertension Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan Chronic Thromboembolic Pulmonary Hypertension Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia Chronic Thromboembolic Pulmonary Hypertension Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India Chronic Thromboembolic Pulmonary Hypertension Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America Chronic Thromboembolic Pulmonary Hypertension Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Bottom-up and Top-down Approaches for This Report
Figure 28. Data Triangulation
Figure 29. Key Executives Interviewed
肺動脈性肺高血圧症（PAH）の世界市場（～2026年） Market Analysis and Insights: Global Pulmonary Arterial Hypertension (PAH) Market The global Pulmonary Arterial Hypertension (PAH) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Pulmonary Arterial Hypertension (PAH) S…- 慢性閉塞性肺疾患（COPD）の世界市場（～2026年） Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time. Eve…
- 慢性閉塞性肺疾患治療の世界市場（～2026年） Market Analysis and Insights: Global Chronic Obstructive Pulmonary Disease Treatment Market The global Chronic Obstructive Pulmonary Disease Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Chronic Obstructive…
- 肺ドラッグデリバリーシステム（PDDS）の世界市場（～2026年） Market Analysis and Insights: Global Pulmonary Drug Delivery System (PDDS) Market The global Pulmonary Drug Delivery System (PDDS) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Pulmonary Drug Delivery System (PDDS) S…
- 特発性肺線維症（IPF）の世界市場（～2026年） Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs become thick and stiff over time. As a result of thickening of lung tissues, brain and other organs are unable receive optimum oxygen. An increase in the incidence and prevalence of fibrotic diseases is the primary driver…